Validation of a liquid chromatographic method for the pharmaceutical quality control of products containing elacridar.

about

Clinical pharmacokinetics of an amorphous solid dispersion tablet of elacridar.Pharmaceutical development of an amorphous solid dispersion formulation of elacridar hydrochloride for proof-of-concept clinical studies.

P2860

Q39172749-BAE28B79-0498-4846-BC93-1040634EF701 Q48384525-57197A12-E97B-4BD9-B62E-4D259D2D5597

P2860

Validation of a liquid chromatographic method for the pharmaceutical quality control of products containing elacridar.

Item

http://www.wikidata.org/entity/Q49179365

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Validation of a liquid chromat ...... products containing elacridar.

@en

Validation of a liquid chromat ...... products containing elacridar.

@nl

type

Item

label

Validation of a liquid chromat ...... products containing elacridar.

@en

Validation of a liquid chromat ...... products containing elacridar.

@nl

prefLabel

Validation of a liquid chromat ...... products containing elacridar.

@en

Validation of a liquid chromat ...... products containing elacridar.

@nl

P1476

Validation of a liquid chromat ...... products containing elacridar.

@en

P2093

Bastiaan Nuijen

http://www.w3.org/2001/XMLSchema#string

Emilia Sawicki

http://www.w3.org/2001/XMLSchema#string

Hilde Rosing

http://www.w3.org/2001/XMLSchema#string

Jan H M Schellens

http://www.w3.org/2001/XMLSchema#string

Jos H Beijnen

http://www.w3.org/2001/XMLSchema#string

Michel J Hillebrand

http://www.w3.org/2001/XMLSchema#string

P2860

Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients

Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein.

A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors.

The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain.

Expression of a multidrug-resistance gene in human tumors and tissues

Brain distribution and bioavailability of elacridar after different routes of administration in the mouse.

Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application.

The role of transporters in the pharmacokinetics of orally administered drugs.

Review: physical chemistry of solid dispersions.

Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability.

P304

268-275

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JPHA.2016.04.005

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29403992

http://www.w3.org/2001/XMLSchema#string

P921

quality control

P932

5762608

http://www.w3.org/2001/XMLSchema#string

Validation of a liquid chromatographic method for the pharmaceutical quality control of products containing elacridar.

about

P2860

P2860

Validation of a liquid chromatographic method for the pharmaceutical quality control of products containing elacridar.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932